Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Becomes First Shop to Sign On to Crucell’s PER.C6 Vendor Network

NEW YORK (GenomeWeb News) - Dutch biotech Crucell and DSM Biologics today said that Invitrogen will become the first company to enter the partnership's licensing business, Vendor Network, for monoclonal antibodies and recombinant proteins.
 
Invitrogen currently uses the Network's PER.C6 technology through its PD-Direct clone-generation services. As part of the deal, Invitrogen "will continue to develop and optimize clone generation solutions specifically tailored to the PER.C6 human cell line," Crucell and DSM said in a statement.
 
The firms created the Vendor Network to develop and provide tools and services specifically tailored to PER.C6. It will comprise tool and service providers that offer, among other things, PER.C6 clone-generation programs, media, bioreactor and other production equipment and devices, and process development services.
 
As a participating vendor, Invitrogen "will ensure ongoing innovation of unique processes and products that enhance the performance of the PER.C6 technology platform" and use its marketing and sales forces "to offer PER.C6-related goods and services, thereby increasing the exposure of the PER.C6 brand worldwide."

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.